Compare
Siga Technologies Inc vs Cytokinetics Inc vs Standard Biotools Inc. vs ARS Pharmaceuticals, Inc.
| Latest fiscal year | Siga Technologies Inc SIGA | Cytokinetics Inc CYTK | Standard Biotools Inc. LAB | ARS Pharmaceuticals, Inc. SPRY |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $94.57M | $88.04M | $85.33M | $84.28M |
| Revenue growth (YoY) | -31.8% | +376.6% | -6.2% | -5.5% |
| Gross margin | 68.6% (computed) | n/a | 49.9% | n/a |
| Operating margin | 25.1% | -695.4% | -129.2% | -212.9% |
| Net margin | 24.6% | -891.6% | -87.8% | -203.3% |
| Net income | $23.28M | -$784.96M | -$74.90M | -$171.30M |
| EPS (Diluted) | $0.32 | -$6.54 | -$0.20 | -$1.74 |
| Operating cash flow | $43.47M | -$510.01M | -$74.34M | -$170.87M |
| Free cash flow | n/a | -$534.82M | -$82.65M | -$171.21M |
| Cash & equivalents | $154.97M | $122.52M | $120.86M | $41.32M |
| Total assets | $219.47M | $1.42B | $567.75M | $327.65M |
| Total liabilities | $20.65M | $2.08B | $143.46M | $213.39M |
| Shareholders' equity | $198.82M | -$659.62M | $424.29M | $114.26M |
| Return on year-end equity | 11.7% | n/a | -17.7% | -149.9% |
| Shares outstanding | 71.61M | 122.94M | 386.38M | 99.29M |
Revenue, most recent five fiscal years
| Fiscal year | Siga Technologies Inc | Cytokinetics Inc | Standard Biotools Inc. | ARS Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $94.57M Ended 2025-12-31 | $88.04M Ended 2025-12-31 | $85.33M Ended 2025-12-31 | $84.28M Ended 2025-12-31 |
| 1 year earlier | $138.72M Ended 2024-12-31 | $18.47M Ended 2024-12-31 | $91.01M Ended 2024-12-31 | $89.15M Ended 2024-12-31 |
| 2 years earlier | $139.92M Ended 2023-12-31 | $7.53M Ended 2023-12-31 | $106.34M Ended 2023-12-31 | $30.0K Ended 2023-12-31 |
| 3 years earlier | $110.78M Ended 2022-12-31 | $94.59M Ended 2022-12-31 | $97.95M Ended 2022-12-31 | $1.32M Ended 2022-12-31 |
| 4 years earlier | $133.67M Ended 2021-12-31 | $70.43M Ended 2021-12-31 | $130.58M Ended 2021-12-31 | $5.51M Ended 2021-12-31 |